Omeprazole

New England Journal of Medicine

Volumn 324, Issue 14, 1991, Pages 965-975

  Maton, Paul N ^a  

^a Oklahoma Foundation for Digestive Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; ANTACID AGENT; CIMETIDINE; RANITIDINE;

CLINICAL TRIAL; DRUG EFFECT; DUODENUM ULCER; HUMAN; REVIEW; STOMACH ACID; STOMACH MUCOSA; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME; DRUG THERAPY; GASTRIN RELEASE; GASTROINTESTINAL DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

DUODENAL ULCER; GASTRIC ACID; GASTRIC MUCOSA; HUMAN; OMEPRAZOLE; STOMACH ULCER; ZOLLINGER-ELLISON SYNDROME;

EID: 0026415879     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199104043241406     Document Type: Review

References (183)

1. Sachs G. The parietal cell as a therapeutic target. Scand J Gastroenterol Suppl 1986; 118:1-10.
2. Sachs G., Carlsson E., Lindberg P., Wallmark B. Gastric H. K-ATPase as therapeutic target. Annu Rev Pharmacol Toxicol 1988; 28:269-284
3. Wallmark B. Omeprazole: mode of action and effect on acid secretion in animals. Scand J Gastroenterol Suppl 1989; 166:12-18
4. Sachs G., Chang H.H., Rabon E., Schackmann R., Lewin M., Saccomani G. A nonelectrogenic H+ pump in plasma membranes of hog stomach. J Biol Chem 1976; 251:7690-7698
5. Wolosin J.M. Ion transport studies with H + -K + -ATPase-rich vesicles: implications for HCI secretion and parietal cell physiology. Am J Physiol 1985; 248:G595-G607.
6. Helander H.F., Hirschowitz B.I. Quantitative ultrastructural studies on inhibited and on partly stimulated gastric parietal cells. Gastroenterology 1974; 67:447-452
7. Smolka A., Helander H.F., Sachs G. Monoclonal antibodies against gastric H+ + K+ ATPase. Am J Physiol 1983; 245:6589-6596
8. Fellenius E., Berglindh T., Sachs G., et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H + + K+) ATPase. Nature 1981; 290:159-161
9. Wallmark B., Larsson H., Humble L. The relationship between gastric acid secretion and gastric H +,K+-ATPase activity. J Biol Chem 1985; 260: 13681-4.
10. Fryklund J., Helander H.F., Elander B., Wallmark B. Function and structure of parietal cells after H+,K+-ATPase blockade. Am J Physiol 1988; 245:G399-G407.
11. Lindberg P., Nordberg P., Alminger T., Brandstrom A., Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 1986; 29:1327-1329
12. Lorentzon P., Jackson R., Wallmark B., Sachs G. Inhibition of H +,K+ATPase by omeprazole in isolated gastric vesicles requires proton transport. Biochim Biophys Acta 1987; 897:41-51.
13. Im W.B., Blakeman D.P., Davis J.P. Irreversible inactivation of the rat gastric (H + -K + )-ATPase in vivo by omeprazole. Biochem Biophys Res Comm 1985; 126:78-82.
14. Regardh C.G. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol Suppl 1986; 118:99-104.
15. Prichard P.J., Yeomans N.K., Mihaly G.W., et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88:64-69
16. Cederberg C., Andersson T., Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl 1989; 166:33-40.
17. Clissold S.P., Campoli-Richards D.M. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986; 32:15-47.
18. Erratum, Drugs 1986; 32:383.
19. Lind T., Cederberg C., Ekenved G., Haglund U., Olbe L. Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin stimulated acid secretion in man. Gut 1983; 24:270-276
20. Lind T., Cederberg C., Forssell H., Olausson M., Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988; 23:1259-1266
21. Festen H.P.M., Tuynman H.A., Defize J., et al. Effect of single and repeated doses of oral omeprazole on gastric acid and pepsin secretion and fasting serum gastrin and serum pepsinogen I levels. Dig Dis Sci 1986; 31:561-566
22. Sharma B.K., Walt R.P., Pounder R.E., Gomes M.D., Wood E.C., Logan L.H. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25:957-964
23. Naesdal J., Bankel M., Bodemar G., Gotthard R., Lundquist G., Walan A. The effect of 20 mg omeprazole daily on serum gastrin, 24-h intragastric acidity, and bile acid concentrations in duodenal ulcer patients. Scand J Gastroenterol 1987; 22:5-12.
24. Lanzon-Miller S., Pounder R.E., Hamilton M.R., et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1:239-251
25. Howden C.W., Payton C.D., Meredith P.A., et al. Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure. Eur J Clin Pharmacol 1985; 28:637-640
26. Naesdal J., Andersson T., Bodemar G., et al. Pharmacokinetics of 14C-omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986; 40:344-351
27. McKee R.F., MacGilchrist A.J., Garden O.J., Forrest A.H., Carter D.C. The antisecretory effect and pharmacokinetics of omeprazole in chronic liver disease. Aliment Pharmacol Ther 1988; 2:429-438
28. Kittang E., Aadland E., Schjonsby H. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut 1985; 26:594-598
29. Kittang E., Aadland E., Schjonsby H., Rohss K. The effect of omeprazole on gastric acidity and absorption of liver cobalamins. Scand J Gastroenterol 1987; 22:156-160
30. Festen H.P.M., Tertoolen J. Malabsorption of protein bound but not unbound cobalamine during treatment with omeprazole. Scand J Gastroenterol Suppl 1989; 166:156. abstract.
31. Pedersen S.A., Kraglund K., Vinter-Jensen L. The effects of omeprazole on gastro-oesophageal pressure, intragastric pH, and the migrating motor complex in fasting healthy subjects. Scand J Gastroenterol 1987; 22:725-730
32. Horowitz M., Hetzel D.J., Buckle P.J., Chatterton B.E., Shearman D.J.C. The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease. Br J Clin Pharmacol 1984; 18:791-794
33. Kaunitz J.D., Sachs G. Identification of a vanadate-sensitive potassium-dependent proton pump from rabbit colon. J Biol Chem 1986; 261:14005-10.
34. Dockray G.J., Gregory R.A. Gastrin. In: Handbook of physiology. Section 6, The gastrointestinal system, vol. 2. Bethesda, Md.: American Physiological Society, 1989: 311-36.
35. Ekman L., Hansson E., Havu N., Carlsson E., Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol Suppl 1985; 108:53-69.
36. Creutzfeldt W., Stockmann F., Conlon J.M., Folsch U.R., Bonatz G., Wulfrath M. Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion 1986; 35:Suppl 1:84-97.
37. Larsson H., Hakanson R., Mattsson H., Ryberg B., Sundler F., Carlsson E. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 1988; 16:267-272
38. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after lifelong inhibition of gastric secretion. Digestion 1986; 35:Suppl 1:42-55.
39. Losec (Omeprazole, MSD). In: Transcript of the proceedings of the Gastrointestinal Drugs Advisory Committee of the FDA, March 15, 1989. Vol. 1. Washington, D.C.: Department of Health and Human Services, 1989: 151-2.
40. Larsson H., Carlsson E., Hakansson R., et al. Time course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion: studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1988; 15:1477-1486
41. Ryberg B., Axelson J., Hakanson R., Sundler F., Mattsson H. Trophic effects of continuous infusion of (Leu15)-gastrin 17 in the rat. Gastroenterology 1990; 98:33-38
42. Havu N., Mattsson H., Ekman L., Carlsson E. Enterochromaffin-cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 1990; 45:189-195
43. Poynter D., Pick C.R., Harcourt R.A., et al. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 1985; 26:1284-1295
44. Spencer A.J., Barbolt T.A., Henry D.C., Eason C.T., Sauerschell R.J., Bonner F.W. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate. Toxicol Pathol 1989; 17:7-15.
45. Mattsson H., Havu N., Bräutigam J., Carlsson K., Lundell L., Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 1991; 100:311-319
46. Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion 1988; 39:61-79.
47. Arnold R., Koop H. Omeprazole: long-term safety. Digestion 1989; 44:Suppl 1:77-86.
48. Penston J., Wormsley K.G. Achlorhydria: hypergastrinaemia: carcinoids —a flawed hypothesis? Gut 1987; 28:488-505.
49. Gustavsson S., Adami H.O., Loof L., Nyberg A., Nyren O. Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. Lancet 1983; 2:124-125
50. Cooperative Study. Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. BMJ 1984; 289:525-528
51. Scandinavian Multicentre Study. Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. Scand J Gastroenterol 1984; 19:882-884
52. Prichard P.J., Rubinstein D., Jones D.B., et al. Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. BMJ 1985; 290:601-603
53. Naesdal J., Lind T., Bergsaker-Aspoy J., et al. The rate of healing of duodenal ulcers during omeprazole treatment. Scand J Gastroenterol 1985; 20:691-695
54. Bader J.-P., Modigliani R., Soule J.C., et al. An open trial of omeprazole in short-term treatment of duodenal ulcer. Scand J Gastroenterol Suppl 1986; 118:177-178
55. Huttemann W., Rohner H.G., duBosque G., et al. 20 versus 30 mg omeprazole once daily: effect on healing rates in 115 duodenal ulcer patients. Digestion 1986; 33:117-120
56. Belgian Multicentre Group. Rate of duodenal ulcer healing during treatment with omeprazole: a double-blind comparison of a daily dose of 30 mg versus 60 mg. Scand J Gastroenterol Suppl 1986; 118:175-176
57. Karvonen A.-L., Keyrilainen O., Uusitalo A., et al. Effects of omeprazole in duodenal ulcer patients. Scand J Gastroenterol 1986; 21:449-454
58. Rinetti M., Vezzadini P., Jonsson E., Tomasetti P., Labo G. Effect and tolerability of omeprazole in the treatment of duodenal ulcer disease. Drugs Exp Clin Res 1986; 12:701-705
59. Graham D.Y., McCullough A., Sklar M., et al. Omeprazole versus placebo in duodenal ulcer healing: the United States experience. Dig Dis Sci 1990; 35:66-72.
60. Lauritsen K., Anderson B.N., Havelund T., et al. Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double blind comparative trial. Aliment Pharmacol Ther 1989; 3:59-67.
61. Lauritsen K., Rune S.J., Bytzer P., et al. Effect of omeprazole and cimetidine on duodenal ulcer: a double-blind comparative trial. N Engl J Med 1985; 312:958-961
62. Classen M., Dammann H.G., Domschke W., et al. Short-term therapy of duodenal ulcer with omeprazole and ranitidine: results of a German multicenter study. Dtsch Med Wochenschr 1985; 110:210-215
63. Bardhan K.D., Bianchi-Porro G., Bose K., et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 1986; 8:408-413
64. Hetzel D.J., Korman M.G., Hansky J., et al. A double blind multicentre comparison of omeprazole and cimetidine in the treatment of duodenal ulcer. Aust N Z J Med 1986; 16:Suppl 3:595. abstract.
65. Hallberg D., Backman L., Hellstrom M., et al. The effect of omeprazole and ranitidine on ulcer healing in treatment of duodenal ulcer patients. Dig Dis Sci 1986; 31:Suppl 10:280S. abstract.
66. Hui W.M., Lam S.K., Lau W.Y., et al. Omeprazole (OME) vs ranitidine (RAN) for duodenal ulcer (DU) — one-week, low-dose regimens and factors affecting healing. Gastroenterology 1987; 93:A1443. abstract.
67. Gustavsson S., Nyren O., Adami H.-O., et al. Omeprazole heals duodenal and prepyloric ulcers faster than cimetidine — a single-centre trial. Gastroenterology 1987; 92:1420. abstract.
68. Bigard M.A., Isal J.P., Galmiche J.P., Ebrard F., Bader J.P. Comparative efficacy of omeprazole and cimetidine in the treatment of duodenal ulcer in the acute stage: a French multicenter, controlled therapeutic trial. Gastroenterol Clin Biol 1987; 11:753-757
69. Barbara L., Blasi A., Cheli R., et al. Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicenter study. Hepatogastroenterology 1987; 34:229-232
70. Archambault A.P., Pare P., Bailey R.J., et al. Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. Gastroenterology 1988; 94:1130-1134
71. Marks I.N., Winter T.A., Lucke W., et al. Omeprazole and ranitidine in duodenal ulcer healing. S Afr Med J 1988; 74:Suppl:54-56
72. Van Deventer G.M., Cagliola A., Whipple J., Humphries T. Duodenal ulcer healing with omeprazole: a multicenter, double-blind, ranitidine controlled study. Gastroenterology 1988; 94:A476. abstract.
73. Dahlgren S., Domellof L., Hradsky M., et al. The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms. Aliment Pharmacol Ther 1988; 2:483-492
74. Crowe J.P., Wilkinson S.P., Bate C.M., et al. Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Aliment Pharmacol Ther 1989; 3:83-92.
75. McFarland R.J., Bateson M.C., Green J.R., et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990; 98:278-283
76. Mulder C.J.J., Tijtgat G.N.J., Cluysenaer O.J.J., et al. Omeprazole (20 mg om) versus ranitidine (150 mg om) in duodenal ulcer healing and pain relief. Aliment Pharmacol Ther 1989; 3:445-452
77. Chalmers T.C., Buyse M.E. Meta-analysis. In: Chalmers TC, ed. Data analysis for clinical medicine: the quantitative approach to patient care in gastroenterology. Rome: International University Press, 1988: 75-84.
78. Tytgat G.N.J., Lamers C.B.H.W., Hameeteman W., Jansen J.M.B.J., Wilson J.A. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther 1987; 1:31-38
79. Pen J.H., Michielsen P.P., Pelckmans P.A., Van Maercke Y.M. Omeprazole in the treatment of H2-resistant gastro-duodenal ulcers. Gastroenterology 1988; 94:A348. abstract.
80. Brunner G., Creutzfeldt W., Harke U., Lamberts R. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion 1988; 39:80-90.
81. Brunner G., Creutzfeldt W. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol Suppl 1989; 166:101-105
82. Bardhan K.D., Dhande D., Hinchliffe R.F.C., et al. Omeprazole in the treatment of ultra refractory duodenal ulcer. Gastroenterology 1988; 94:A22. abstract.
83. Guerreiro A.S., Neves B.C., Quina M.G. Omeprazole in the treatment of peptic ulcer resistant to H2 receptor antagonists. Aliment Pharmacol Ther 1990; 4:309-314
84. Bardhan K.D., Naesdal J., Bianchi Porro G., et al. Omeprazole (OM) in the treatment of refractory peptic ulcer (RPU). Gastroenterology 1988; 94:A22. abstract.
85. Delchier J.C., Isal J.P., Eriksson S., Soule J.C. Double-blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut 1989; 30:1173-1178
86. Grant S.M., Langtry H.D., Brogden R.N. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 37:801-870
87. McLean A.J., Harcourt S.M., McNeil J.J. Relapse rate as a major determinant of drug selection in peptic ulcer therapy. Drugs 1988; 35:329-333
88. Farup P.G., Rosseland A.R., Halvorsen L., Anderson O.F., Bernklev T. Duodenal ulcer treated with omeprazole: healing and relapse rates: does treatment duration influence subsequent remission? Scand J Gastroenterol 1989; 24:1107-1112
89. Brook C.W., Yeomans N.D., McCarthy P.G., Dudley F.J., Smallwood R.A. Relapse of duodenal ulceration after healing with omeprazole. Med J Aust 1987; 147:595-597
90. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99:345-351
91. Huttemann W. Short-term treatment of gastric ulcer with once daily omeprazole. Scand J Gastroenterol Suppl 1986; 118:179. abstract.
92. Farup P.G., Darle N., Falk A., Bernklev T. Treatment of benign gastric ulcer with omeprazole 30 mg once daily. Curr Ther Res 1988; 43:872-877
93. Francavilla A., Ingrosso A., Mongelli A., et al. Omeprazole: a new antisecretory drug in the treatment of gastric ulcer. Dig Dis Sci 1986; 31:Suppl 10:335S. abstract.
94. Classen M., Dammann H.G., Domschke W., et al. Healing rates following omeprazole and ranitidine treatment of gastric ulcer: results of a German multicenter study. Dtsch Med Wochenschr 1985; 110:628-633
95. Barbara L., Saggioro A., Olsson J., Cisternino M., Franceschi M. Omeprazole 20 mg om and ranitidine 150 mg bd in the healing of benign gastric ulcers — an Italian multicentre study. Gut 1987; 28:A1341. abstract.
96. Bate C.M., Wilkinson S.P., Bradby G.V.H., et al. Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut 1989; 30:1323-1328
97. Walan A., Bader J.-P., Classen M., et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320:69-75.
98. Danish Omeprazole Study Group. Omeprazole and cimetidine in the treatment of ulcers of the body of the stomach: a double-blind comparative trial. BMJ 1989; 298:645-647
99. Lauritsen K., Rune S.J., Wulff H.R., et al. Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. Gut 1988; 29:249-253
100. Danish Omeprazole Study Group. Relapse of gastric ulcers after healing with omeprazole and cimetidine: a double-blind follow-up study. Scand J Gastroenterol 1989; 24:557-560
101. Dent J., Downton J., Heddle R., et al. Effects of omeprazole on peptic esophagitis and esophageal motility and pH. Scand J Gastroenterol 1986; 118:181. abstract.
102. Hetzel D.J., Dent J., Reed W.D., et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95:903-912
103. Richter J.E. A critical review of current medical therapy for gastroesophageal reflux disease. J Clin Gastroenterol 1986; 8:Suppl 1:72-80.
104. Dammann H.G., Blum A.L., Lux G., et al. Different healing tendencies of reflux esophagitis following omeprazole and ranitidine: results of a German-Austrian-Swiss multicenter trial. Dtsch Med Wochenschr 1986; 111:123-128
105. Klinkenberg-Knol E.C., Jansen J.B.M.J., Festen H.P.M., Meuwissen S.G.M., Lamers C.B.H.W. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. Lancet 1987; 1:349-351
106. Vantrappen G., Rutgeerts L., Schurmans P., Coenegrachts J.L. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33:523-529
107. Sandmark S., Carlsson R., Fausa O., Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23:625-632
108. Havelund T., Laursen L.S., Skoubo-Kristensen E., et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. BMJ 1988; 296:89-92.
109. Zeitoun P., Rampal P., Barbier P., Isal J.P., Eriksson S., Carlsson R. Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux: results of a double-blind randomized multicenter trial in France and Belgium. Gastroenterol Clin Biol 1989; 13:457-462
110. Dehn T.C.B., Shepherd H.A., Colin-Jones D., Kettlewell M.G.W., Carroll N.J. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 1990; 31:509-513
111. Hetzel D.J., Bonnin M. Long term management of hemorrhagic esophagitis with cimetidine and omeprazole. Aust N Z J Med 1986; 16:226-228
112. Hameeteman W., Tytgat G.N. Healing of chronic Barrett ulcers with omeprazole. Am J Gastroenterol 1986; 81:764-6
113. Fausa O., Aadland E., Lotveit T. Omeprazole in the treatment of patients with severe erosive oesophagitis resistant to treatment with H2-receptor antagonists. Scand J Gastroenterol 1987; 135:38. abstract.
114. Bardhan K.D., Morris P., Thompson M., et al. Value of omeprazole in the management of erosive esophagitis refractory to high dose cimetidine. Gut 1987; 28:A1375. abstract.
115. Klinkenberg-Knol E.C., Jansen J.B.M.J., de Bruyne J.W., et al. long-term efficacy and safety of omeprazole (OME) on healing and prevention of resistant reflux esophagitis. Gastroenterology 1988; 94:A230. abstract.
116. Lundell L., Backman L., Ekstrom P., et al. Omeprazole or high dose ranitidine in the treatment of patients with reflux esophagitis not responding to #x0027;standard doses#x0027; of H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4:145-156
117. Maton P.N., Gardner J.D., Jensen R.T. Diagnosis and management of Zollinger-Ellison syndrome. Endocrinol Metab Clin North Am 1989; 18:519-543
118. Maton P.N., Frucht H., Vinayek R., Wank S.A., Gardner J.D., Jensen R.T. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988; 94:294-299
119. Miller L.S., Vinayek R., Frucht M., Gardner J.D., Jensen R.T., Maton P.N. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98:341-346
120. Bianchi A., Delchier J.C., Soule J.-C., Payen D., Bader J.-P. Control of acute Zollinger-Ellison syndrome with intravenous omeprazole. Lancet 1982; 2:1223-1224
121. Öberg K., Lindström H. Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazole. Lancet 1983; 1:66-67
122. Lamers C.B.H.W., Lind T., Moberg S., Jansen J.B.M.J., Olbe L. Omeprazole in Zollinger-Ellison syndrome: effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. N Engl J Med 1984; 310:758-761
123. Vezzadini P., Tomassetti P., Toni R., Bonora G., Labo G. Omeprazole in the medical treatment of Zollinger-Ellison syndrome. Curr Ther Res 1984; 35:772-776
124. McArthur K.E., Collen M.J., Maton P.N., et al. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology 1985; 88:939-944
125. Bardram L., Stadil F. Omeprazole in the Zollinger-Ellison syndrome. Scand J Gastroenterol 1986; 21:374-378
126. Delchier J.-C., Soule J.-C., Mignon M., et al. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. Dig Dis Sci 1986; 31:693-699
127. Lloyd-Davies K.A., Rutgersson K., Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4 year international study. Aliment Pharmacol Ther 1988; 2:13-32.
128. Hirschowitz B.I., Deren J., Raufman J.P., LaMont B., Berman R., Humphries T. A multicenter U.S. study of omeprazole treatment of Zollinger-Ellison syndrome (ZES). Gastroenterology 1988; 94:AI88. abstract.
129. Corleto V., Puoti M., Annibale B., et al. Loss of efficacy of famotidine (FMT) in the control of gastric acid secretion in patients with Zollinger-Ellison syndrome (ZES), reversed by omeprazole (OMP). Gastroenterology 1988; 94:A79. abstract.
130. Cadranel J.F., Ruszniewski P., Elouaer-Blanc L., et al. Long-term efficacy and tolerability of omeprazole in 20 patients with severe Zollinger-Ellison syndrome. Gastroenterol Clin Biol 1989; 13:654-662
131. Meijer J.L., Jansen J.B., Lamers C.B. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. Digestion 1989; 44:Suppl 1:31-39
132. Bardram L., Stadil F. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome. Scand J Gastroenterol Suppl 1989; 166:95-100.
133. Maton P.N., Vinayek R., Frucht H., et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989; 97:827-836
134. Solvell L. The clinical safety of omeprazole. Scand J Gastroenterol Suppl 1989; 166:106-110
135. Dowie J.L., Smith J.E., MacGilchrist A.J., et al. In vivo and in vitro studies of the site of inhibitory action of omeprazole on adrenocortical steroidogenesis. Eur J Clin Pharmacol 1988; 35:625-629
136. Jensen J.C., Gugler R. Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol 1986; 21:328-330
137. Diaz D., Fabre I., Daujat M., et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99:737-747
138. Sutfin T., Balmer K., Bostrom H., Eriksson S., Hoglund P., Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11:176-184
139. Gugler R., Jensen J.C. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89:1235-1241
140. Prichard P.J., Walt R.P., Kitchingman G.K., et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24:543-545
141. Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47:79-85.
142. Henry D.A., Somerville K.W., Kitchingman G., Langman M.J. Omeprazole: effects on oxidative drug metabolism. Br J Clin Pharmacol 1984; 18:195-200.
143. Henry D., Brent P., Whyte I., Mihaly G., Devenish-Mears S. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33:369-373
144. Gugler R., Jensen J.C. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 1987; 33:133-137
145. Carney J.A., Go V.L.W., Fairbanks V.F., Moore S.B., Alport E.C., Nora F.E. The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med 1983; 99:761-766
146. Hodges J.R., Isaacson P., Wright R. Diffuse enterochromaffin-like (ECL) hyperplasia and multiple carcinoids: a complication of pernicious cell anemia. Gut 1981; 22:237-241
147. Wilander E. Achylia and the development of gastric carcinoids. Virchows Arch [Pathol Anat] 1981; 394:151-160
148. MacDonald R.A. A study of 356 carcinoids of the gastrointestinal tract: report of four new cases of the carcinoid syndrome. Am J Med 1956; 21:867-878
149. Godwin J.D. II. Carcinoid tumors: an analysis of 2,837 cases. Cancer 1975; 36:560-569
150. Harvey R.F., Bradshaw M.J., Davidson C.M., Wilkinson S.P., Davies P.S. Multifocal gastric carcinoid tumors, achlorhydria, and hypergastrinaemia. Lancet 1985; 1:951-954
151. Borch K., Renvall H., Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88:638-648
152. Lehtola J., Karttunen T., Krekela I., Niemela S., Rasanen O. Gastric carcinoids with minimal or no macroscopic lesion in patients with pernicious anemia. Hepatogastroenterology 1985; 32:72-76
153. Stockbrugger R.W., Menon C.G., Beilby J.O.W., Mason R.R., Cotton P.B. Gastroscopic screening in 80 patients with pernicious anemia. Gut 1983; 24:1141-1147
154. Olbe L., Lundell L., Sundler F. Antrectomy in a patient with ECL-cell gastric carcinoids and pernicious anemia. Gastroenterol Int 1988; 1:Suppl 1:340.
155. Richards A.T., Hinder R.A., Harrison A.C., et al. Gastric carcinoid tumours associated with hypergastrinaemia and pernicious anemia — regression of tumors by antrectomy: a case report. S Afr Med J 1987; 72:51-53
156. Hirschowitz B.I., Griffith J., Pellegrin D., Cummings O.W. Rapid regression of ECL-cell gastric carcinoids in 3 patients with pernicious anemia after elimination of hypergastrinemia by antrectomy. Gastroenterology 1990; 98:A286. abstract.
157. Solcia E., Capella C., Fiocca R., Cornaggia M., Bosi F. The gastroenteropancreatic endocrine system and related tumors. Gastroenterol Clin North Am 1989; 18:671-674
158. Maton P.N., Lack E.E., Collen M.J., et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990; 99:943-950
159. Carlsson E., Larsson H., Mattsson H., Ryberg B., Sundell G. Pharmacology and toxicology of omeprazole — with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 1986; 118:31-38
160. Allen J.M., Adrian T.E., Webster J., Howe A., Bloom S.R. Effect of single dose of omeprazole on the gastrointestinal peptide response to food. Hepatogastroenterology 1984; 31:44-46
161. Walsh J.H., Sytnik B., Maxwell V., et al. Reversibility of plasma gastrin changes induced by omeprazole or ranitidine in man. Am J Gastroenterol 1988; 83:1042. abstract.
162. Lind T., Cederberg C., Forssell H., Olausson M., Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988; 23:1259-1266
163. Jansen J.B.M.J., Klinkenberg-Knol E.C., Meuwissen S.G.M., et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99:621-628
164. Lanzon-Miller S., Pounder R.E., Hamilton M.R., et al. Twenty four hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer or pernicious anemia. Aliment Pharmacol Ther 1987; 1:225-227
165. Solcia E., Rindi G., Havu N., Elm G. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol Suppl 1989; 166:129-137
166. Lamberts R., Creutzfeldt W., Stockmann F., Jacubaschke U., Maas S., Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 38:126-135
167. Helander H.F. Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome. Digestion 1986; 35:Suppl 1:123-129
168. Dayal Y., Berlin R., Collen M., Bhatnager R. Does prolonged omeprazole administration affect enterochromaffin-like cell populations in hypersecretors? Gastroenterology 1989; 96:A113. abstract.
169. Lehy T., Mignon M., Cadiot G., et al. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 1989; 96:1029-1040
170. Bardram L., Thomsen P., Stadil F. Gastric endocrine cells in omeprazole-treated and untreated patients with Zollinger-Ellison syndrome. Digestion 1986; 35:Suppl 1:116-122
171. Crobach L.F., Jansen J.B., Lamers C.B. Effect of intermittent weekend therapy with omeprazole on basal and bombesin- and pentagastrin-stimulated gastric acid and serum gastrin. Scand J Gastroenterol 1988; 23:407-412
172. Hewsen E.G., Yeomans M.D., Angus P.W., et al. Effect of “weekend therapy” with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients. Gut 1988; 29:1715-1720
173. Lauritsen K., Anderson B.N., Laursen L.S., et al. Weekend administration of omeprazole in prevention of duodenal ulcer relapse: a double blind trial. Gastroenterology 1989; 96:A289. abstract.
174. Isal J.P., Zeitoun P., Barbier P., Cayphas J.P., Carlsson R. Comparison of two dosage regimens of omeprazole — 10 mg once daily and 20 mg weekends — as prophylaxis against recurrence of reflux esophagitis. Gastroenterology 1990; 98:A63. abstract.
175. Sharma B.K., Santana I.A., Wood E.C., et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. BMJ 1984; 289:717-719
176. Howden C.W., Hunt R.H. Relationship between gastric secretion and infection. Gut 1987; 28:96-107.
177. Wormsley K.G. Assessing the safety of drugs for the long-term treatment of peptic ulcers. Gut 1984; 25:1416-1423
178. Talley N.J., Chute C.G., Larson D.E., Epstein R., Lydick E.G., Melton L.J. III. Risk for colorectal adenocarcinoma in pernicious anemia: a population-based cohort study. Ann Intern Med 1989; 111:738-742
179. Brinton L.A., Gridley G., Hrubec Z., Hoover R., Fraumeni J.F. Jr. Cancer risk following pernicious anaemia. Br J Cancer 1989; 59:810-813
180. Jansen J.B.M.J., Lundbord P., Baak L.C., et al. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 1988; 29:75-80.
181. Vinayek R., Frucht H., London J.F., et al. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990; 99:10-16
182. Erratum, Gastroenterology 1990; 99:905.
183. Brunner G., Chang J. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial. Digestion 1990; 45:217-225